ReviewGeroScience2026
Circulating microRNAs in pulmonary arterial hypertension: biomarkers for diagnosis, prognostic stratification, and treatment.
Review in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Physiology-Based Diagnosis and Management of Bronchopulmonary Dysplasia Associated Pulmonary Hypertension (BPD-PH).Children (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Pulmonary arterial hypertension (PAH) is a rare and progressive and life-threatening clinical condition characterized by elevated mean pulmonary arterial pressure (mPAP ≥ 20 mmHg at rest), increased pulmonary vascular resistance (PVR ≥ 2 Wood units), and normal pulmonary arterial wedge pressure. PAH group 1 comprises idiopathic, heritable, and drug- or toxin-induced forms, as well as cases associated with connective tissue diseases, HIV infection, portal hypertension, congenital heart disease, schistosomiasis, persistent pulmonary hypertension of the newborn, and pulmonary veno-occlusive disease (PVOD)/pulmonary capillary hemangiomatosis. The diagnosis of PAH is frequently delayed, and clinical outcomes remain poor in a significant proportion of patients, although several targeted therapies, acting on the endothelin (ET-1), nitric oxide (NO), and prostacyclin pathways, have been developed, and novel agents (i.e., sotatercept) are showing promising results in clinical trials. Circulating microRNAs (miRNAs) have emerged as promising biomarker candidates for risk stratification and prediction of therapeutic response in PAH group 1. These small non-coding RNAs that regulate gene expression at the post-transcriptional level are released into the circulation either actively, via extracellular vesicles such as exosomes and microvesicles, or passively as a result of cell damage. These features confer remarkable stability in biological fluids, making circulating miRNAs particularly attractive not only as innocent bystanders but also as factors actively involved in the pathogenesis of the disease. The aim of this review is to provide an overview of the role of circulating miRNAs in PAH group 1, with a focus on their diagnostic, prognostic, and therapeutic potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.